Join the Contact Dermatitis group to help and get support from people like you.
Contact Dermatitis News
Related terms: Allergic Dermatitis, Dermatitis, Allergic, Dermatitis, Contact
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
WEDNESDAY, April 23, 2025 – Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in JAMA Ophthalmology. Yung-Yu ...
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
FRIDAY, March 14, 2025 – Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in P...
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
FRIDAY, March 14, 2025 – Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment,...
Early Childhood Stressful Life Events Linked to Increased Eczema Activity
WEDNESDAY, Feb. 5, 2025 – For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for disease activity, according to a study published...
Study IDs Signs of Topical Steroid Withdrawal in Atopic Dermatitis
WEDNESDAY, Jan. 22, 2025 – Self-reported manifestations of topical steroid withdrawal (TSW) in atopic dermatitis (AD) include erythema, desquamation, dryness, and oozing affecting the face, neck,...
FDA Expands Approval of Vtama to Include Atopic Dermatitis
THURSDAY, Dec. 19, 2024 – The U.S. Food and Drug Administration has approved Vtama (tapinarof) 1 percent cream for an additional indication – the topical treatment of atopic dermatitis in adult and...
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Dec. 18, 2024 – The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. ...
Dupilumab Efficacious for Atopic Dermatitis in Young Children
WEDNESDAY, Dec. 11, 2024 – Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published in the December issue of Advances in Therapy. ...
FDA Medwatch Alert: Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health
October 30, 2024 – FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly...
Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
FRIDAY, Oct. 25, 2024 – Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published...
Are 'Elimination Diets' Much Help Against Child Eczema?
FRIDAY, Oct. 25, 2024 – Cutting certain foods from a child’s diet isn’t likely to improve their eczema symptoms, a new study finds. Eczema, also known as atopic dermatitis, results from an ove...
Eczema Could Be Linked to Poorer Leg Artery Function
TUESDAY, Oct. 22, 2024 – The skin condition eczema appears to be linked to a serious condition that can end in leg amputation, a new study finds. People with eczema are at significantly higher risk...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 – The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis....
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
WEDNESDAY, Sept. 4, 2024 – The association of prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) with the risk for childhood atopic dermatitis (AD) varies based on the maternal ...
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
FRIDAY, Aug. 30, 2024 – Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, ...
Further information
Related condition support groups
Related drug support groups
prednisone, methylprednisolone, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, dupilumab, halobetasol